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We developed specific, C-terminal radioimmunoassays for three proglucagon (PG) fragments: PG 151-158, PG 151-160 
and PG 126159 (glucagon-like peptide- (GLP-2)) in order to determine the exact C-terminal sequence of the newly 
isolated GLP-2 in man and pig. The antigens and the antisera showed no mutual cross-reactivity. By gel filtration of 
extracts of pig and human small intestine, the immunoreactivity eluting at the position of GLP-2 was identified by the 
radioimmunoassays for glucagon-like peptide- (PG 126159) and for PG 151-158, whereas the assay for PG 151-160 
was completely negative. We conclude that the C-terminal amino acid residue of pig and human ileal GLP-2 is PG 158. 
Thus the basic residues, PG 159 and 160 are removed uring its processing in the small intestine. 
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1. INTRODUCTION 
The structure of human proglucagon (PG) was 
predicted at first in 1983 by Bell and co-workers, 
from the nucleotide sequence of a single gene en- 
coding glucagon. PG was suggested to consist of 
159 amino acid residues (with a C-terminal 
arginine residue) [l]. In 1984, however, Heinrich 
and co-workers, who sequenced a structurally 
similar gene encoding for glucagon in the rat, sug- 
gested that human proglucagon, like rat pro- 
glucagon, consisted of 160 amino acids (with an 
additional C-terminal basic residue, lysine [2]). 
The proglucagon sequence consists of three 
glucagon-like sequences flanked by dibasic poten- 
tial cleavage sites: glucagon itself and two C- 
terminal amino acid sequences with approximately 
50% sequence homology with glucagon, glucagon- 
like peptide-l (GLP-1) and glucagon-like peptide- 
(GLP-2) (fig.1). Both GLP-l-immunoreactivity 
(IR) and GLP-ZIR are found in gel filtrations of 
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mammalian small intestinal extracts (e.g. human 
and pig [3,4]). The elution position of GLP-ZIR 
corresponds to a peptide of a molecular mass of 
about 3 kDa. As deduced from the PG sequence 
post-translational cleavage of proglucagon to ob- 
tain GLP-2 would be expected to occur, N- 
terminally, at the site of the dibasic amino acids at 
residue numbers 124-125. For the C-terminus, 
three possibilities might be considered: (i) no 
modification of the C-terminus of PG; (ii) post- 
translational cleavage of PG with a trypsin-like en- 
doprotease or (iii) C-terminal cleavage of PG first 
with a trypsin-like endoprotease and subsequently 
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Fig. 1. Proglucagon in mammals is a 160 amino acid peptide 
precursor. It consists of an N-terminal peptide which is 
homologous to glicentin-related pancreatic peptide, GRPP (PG 
l-30), and three glucagon-like sequences: glucagon (PG 
33-61), glucagon-like peptide-l (PG 78-107 amide), and 
glucagon-like peptide- (PG 126-158), the two latter peptides 
separated by an intervening sequence of 13 amino acids, the so- 
called spacer peptide- (Sp-2) (PG 111-122 amide). 
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Fig.2. Amino acid sequence of the C-terminus of human 
proglucagon containing the GLP-2 sequence. Peptide 
fragments employed in this study are indicated according to 
their size and position. Crescents represent the antigenic sites of 
the antisera employed. Encircled amino acids represent residues 
in human PC differing from pig PG. 
with a carboxypeptidase-B-like xoprotease. The 
three conceivable C-terminal residues would thus 
be: residues 160, 159 or 158. We recently isolated 
GLP-2 from pig small intestine and found that the 
majority of porcine GLP-2 corresponded to pro- 
glucagon 126-158 and that human GLP-2 cor- 
responded exactly in size to the porcine peptide [5]. 
However, although no traces of further residues 
(in particular basic residues) were found, some 
uncertainty about the exact C-terminal sequence of 
this rather long peptide remained. Thus, to deter- 
mine the exact C-terminal structure of GLP-2, we 
investigated the immunoreactive behaviour of 
GLP-2 in extracts of small intestine from man and 
pig with specific C-terminal radioimmunoassays 
(RIA) against he PG fragments: PG 151-158, PG 
15 1- 160 and a previously developed radioim- 
munoassay for PG 126-159 (GLP-2) (fig.2). 
2. MATERIALS AND METHODS 
PC 151-158, PC 151-160, c~s”~PG 150-158 and c~s”~PG 
150-160 were synthesized on an Applied Biosystems 430A pep- 
tide synthesizer, using a standard BOC-chemistry procedure. 
Resin-bound amino acids and protected amino acids were pur- 
chased from Applied Biosystems (Warrington, England). Pep- 
tides were cleaved from the resin and deprotected by liquid HF 
by a standard procedure [6]. Free peptides were purified on a 
low pressure RP-18 column using acetic acid (2%)/water/ 
ethanol (O-40%) as eluent. Purity was ascertained by amino 
acid, sequence and HPLC (high pressure liquid chroma- 
tography) analyses. Synthetic PG 151-158 and PC 151-160 
were used as standards and for preparation of labelled peptides. 
For the production of antisera c~s”~PG 150-158 and 
c~s’~~PG 150-160 (5 mg each) were coupled to keyhole limpet 
hemocyanin (4 mg) through the cysteine residues using m- 
maleimido-benzoyl-N-hydroxysuccinimide [7]. Rabbits were 
boosted five times each at two week intervals with immunogen 
corresponding to 250,ug of peptides and were bled ten days 
after the last immunization. 
Synthetic PC 151-158 and PC 151-160 were iodinated with 
‘251-labelled Bolton-Hunter reagent according to the manufac- 
turer’s instructions (Amersham, Buckinghamshire, England) 
and purified by gel chromatography before use, as previously 
described [8]. 
For the assay of GLP-2, we used synthetic GLP-2 (PC 
126-159, human sequence, code 7167, Peninsula, Belmont, 
CA, USA) as the standard, lZSI-labelled GLP-2 and antiserum 
1975 raised against synthetic GLP-2, as described in [8]. The an- 
tigenic site for this antiserum has previously been found to be 
located in the C-terminus of the peptide between PG residues 
146 and 158 [8]. 
Standard or sample and antiserum (ab) were incubated (final 
dilution (fd.) of ab 8773 (against PG 151-158) 1:2500; fd. of 
ab 8769 (against PG 151-160) 1:5000; and fd. of ab 1975 
1: 10000 (against PC 126-159)) for 48 h at 4°C. After another 
48 h of incubation with labelled peptide at 4”C, free and bound 
peptides were separated by adsorption to plasma-bound char- 
coal as previously described [8]. 
All possible combinations of the three different antisera, 
labelled peptides and synthetic peptides were studied to reveal 
possible cross-reactions between them. 
2 nmol of synthetic GLP-2 (PG 126-159) in 1.5 ml of saline 
was incubated with 15 ,uI of carboxypeptidase B (art. 2300, 
batch 9623 230, Merck, Darmstadt, FRG) for 2 h at room 
temperature and subsequently applied on a K16/100 column 
packed with G-50 SF (Pharmacia, Sweden), equilibrated and 
eluted in 0.04 mol/l sodium phosphate buffer containing in ad- 
dition 0.1% human serum albumin (reinst, trocken, Behr- 
ingwerke, Marburg, FRG), 2.9 g/l NaCl, 0.04 mmol/l 
thiomersal and 20 mmol/l EDTA at a flow rate of 19 ml/h. All 
fractions were subjected to radioimmunoassay using antisera 
1975 and 8773. The amount of and the elution position of im- 
munoreactive material were compared with those of 2 nmol of 
undigested synthetic GLP-2 applied to the same column. ‘*‘I- 
labelled albumin and **NaCl were added to all samples before 
gel filtration for internal calibration. The measured im- 
munoreactivity was then plotted against &, the coefficient of 
distribution (calculated as (V, - V,)/(V, - V,), where V, is the 
volume of the fraction in question, V, the position of i*sI- 
labelled albumin and Vt the position of **NaCl). 
Pieces of normal human ileum were obtained during surgery 
on the gastrointestinal tract (approved by Local Ethical Com- 
mittee) and immediately frozen. Pieces of pig ileum were 
removed from anaesthetized pigs (strain LYY). Tissues were 
subsequently extracted in acid-ethanol (method II in [9]) and 
subjected to gel filtration on a 50 x 1000 mm column (K 
50/100, Pharmacia, Sweden) packed with Sephadex SF (Phar- 
macia), equilibrated and eluted with 0.5 mol/l acetic acid at a 
flow rate of 60 ml/h. All samples were then subjected to RIAs 
for GLP-2 (PC 126-159), PG 151-158 and PG 151-160. The 
mea&red immunoreactivity was then plotted against &, the 
coefficient of distribution, calculated as described above. 
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3. RESULTS AND DISCUSSION 
In this study we employed specific, C-terminal 
RIAs for each of the three proglucagon fragments: 
PG 151-158, PG 151-160 and PG 126-159, to 
determine the C-terminal residue of GLP-2 in pig 
and human small intestine. 
The experimental detection limit (lowest concen- 
tration to be distinguished from zero) was 
80 pmol/l for both PG 151-158 and PG 151-160. 
The intraassay coefficient of variation was below 
10% for both assays. The specificities of the an- 
tisera are illustrated in tables 1 and 2. As shown in 
table 1, ab 1975 strongly bound labelled synthetic 
GLP-2 (PG 126-159) but not labelled PG 151-158 
or PG 151-160. Ab 8773 strongly bound labelled 
PG 151-158 but not labelled GLP-2 or PG 
15 l- 160. Ab 8769 strongly bound labelled PG 
151-160 but not labelled GLP-2 or PG 151-158. 
Table 2 shows that synthetic GLP-2 (PG 126-159) 
displaced labelled GLP-2 from ab 1975, whereas 
PG fragments, PG 151-158 and PG 151-160, 
were inactive. PG 151-158 displaced labelled PG 
Table 1 
Antiserum specificity 
q q_ ‘=I_ 
PC 126-159 PC 151-158 PG 151-160 
Ab 1975 + _ - 
Ab 8773 - + - 
Ab 8769 _ - + 
The table shows reactions between antisera (1975, 8773 and 
8769) and the three ‘251-labelled peptides. + represents binding 
of ab to labelled peptides and - represents no binding 
Table 2 
Antiserum specificity 
Ab 1975 + Ab 8773 + Ab 8769 + 
‘25f_ ‘=I_ ‘=I_ 
PC 126-159 PC 151-158 PG 151-160 
GLP-2 
PG 126-159 + _ _ 
PG 151-158 - + - 
PG 151-160 - - + 
The table shows displacement of labelled peptides from antisera 
with unlabelled peptides. + represents displacement of labelled 
peptide and - represents no displacement 
151-158 from ab 8773, whereas PG 151-160 and 
GLP-2 did not react. PG 15 l- 160 displaced la- 
belled PG 151-160 from ab 8769, whereas PG 
151-158 and GLP-2 did not react. 
Upon gel filtration of the extracts, an im- 
munoreactive moiety coeluting with synthetic 
GLP-2 was identified with the assays for PG 
126-159 and PG 151-158, whereas the PG 
151-160 assay was negative. Furthermore the PG 
151-158 assay reacted neither with PG 151-160 
nor with PG 126-159, but did react with PG 
126-159 after removal of residue 159 with carbox- 
ypeptidase B (figs 3 and 4). In gel filtrations of ex- 
tracts of pig small intestine, ab 8773 measured 
smaller amounts of GLP-ZIR compared to ab 
1975, probably due to the fact that ab 8773 was 
raised against a human PG fragment from a region 
in which 2 residues differ from the pig sequence 
(PG 152 and 153) [5]. From these data we conclude 
pmol/L 
4 
1.0 Kd 
Fig.3. Gel filtration profile of (A) 2 nmol of synthetic GLP-2 
(PG 126-159) and (B) 2 nmol of synthetic GLP-2 after 
treatment with carboxypeptidase-B. As measured with 
antiserum 1975 (-). As measured with antiserum 8773 
(- - -). GLP-2-immunoreactivity is plotted against Kd, the 
coefficient of distribution, calculated as described. 
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Fig.4. Gel filtration profile of (A) extract of human and (B) 
extract of pig small intestine, as measured with antiserum 1975 
(-), antiserum 8773 (- - - - - ) and antiserum 8769 (+ + +). 
GLP-2-immunoreactivity is plotted against Kd, the coefficient 
of distribution, calculated as described. 
that the amino acid sequence of GLP-2 in pig and 
human small intestine is PG 126-158. 
The GLP-2 sequence is less conserved among 
species than glucagon and GLP-1; human GLP-2 
differs from pig, ox and hamster GLP-2 in 4,4 and 
3 positions, respectively [5,10,11], and is not found 
in fish PG at all [12]. Thus, studies of the 
physiological effects of GLP-2 must be carried out 
with a peptide, the structure of which corresponds 
to that of GLP-2 from the chosen experimental 
animal. 
Synthetic ‘GLP-2’ (= human sequence PG 
126-159) which is commercially available has been 
completely inert except in one study. Hoosein and 
Gurd [13] reported that synthetic ‘GLP-2’ 
stimulated adenylate cyclase in hypothalamus of 
rats, though they were unable to identify receptors 
for GLP-2 in this tissue. Whether the naturally oc- 
curring GLP-2 has similar effects in hypothalamus 
remains to be investigated. 
GLP-ZIR has been shown to be produced and 
co-secreted with the insulinotropic peptide GLP-1 
and glicentin [4] from small intestine of pig, and to 
be released into the circulation in man after a 
mixed meal [8]. Further studies with synthetic 
replicas of species-specific GLP-2 will allow the 
delineation of its eventual hormonal functions. 
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